Journal of the American Heart Association
-
Randomized Controlled Trial Multicenter Study
MR-proADM as a Prognostic Marker in Patients With ST-Segment-Elevation Myocardial Infarction-DANAMI-3 (a Danish Study of Optimal Acute Treatment of Patients With STEMI) Substudy.
Midregional proadrenomedullin (MR-proADM) has demonstrated prognostic potential after myocardial infarction (MI). Yet, the prognostic value of MR-proADM at admission has not been examined in patients with ST-segment-elevation MI (STEMI). ⋯ URL: http:/www.ClinicalTrials.gov/. Unique identifiers: NCT01435408 and NCT01960933.